Shattuck Labs Stock Surges on Analyst Coverage and Drug Development Progress
Shattuck Labs (NASDAQ: STTK) saw its stock rise nearly 5% in Monday trading after two analysts upgraded the clinical-stage biotech. TD Cowen's Stacy Ku initiated coverage with a 'buy' rating, while Raymond James analyst Martin Auster gave it an even more bullish 'strong buy' at $18 per share—over twice the recent closing price of $7.90. The optimism centers on Shattuck’s drug candidate SL-325, which is in Phase 2b trials for inflammatory bowel disease and has a novel mechanism targeting specific receptors that could differentiate it from competitors. Auster estimates its potential market at over $20 billion if successful. SL-325's progress to advanced clinical testing marks significant development milestones for the company, increasing investor interest as results may determine Shattuck’s long-term viability and growth prospects.
Topics: analyst ratings biotech clinical trials